Detalhe da pesquisa
1.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(2): 123-35, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028407
2.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412456
3.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
N Engl J Med
; 371(23): 2189-2199, 2014 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25409260
4.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Lancet Oncol
; 17(7): 883-895, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27269741
5.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Lancet Oncol
; 16(3): 257-65, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25704439
6.
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Drug Metab Dispos
; 38(11): 2049-59, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20668249
7.
Transcriptional regulatory code of a eukaryotic genome.
Nature
; 431(7004): 99-104, 2004 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-15343339
8.
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
JAMA Oncol
; 5(10): 1411-1420, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31343665
9.
Reconstructing dynamic regulatory maps.
Mol Syst Biol
; 3: 74, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17224918
10.
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
J Clin Oncol
; 36(28): 2836-2844, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30110194
11.
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Neuro Oncol
; 20(5): 674-686, 2018 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29106665
12.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 34(25): 2980-7, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354485
13.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 34(25): 2969-79, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354481
14.
Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Arch Pathol Lab Med
; 137(6): 820-7, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23030695
15.
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Eur J Cancer
; 49(8): 1815-24, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23490650
16.
The cetuximab experience: developing predictive biomarkers in oncology.
Per Med
; 8(2): 149-159, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29783412
17.
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
J Clin Oncol
; 28(6): 918-27, 2010 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20100958
18.
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
J Clin Oncol
; 25(22): 3230-7, 2007 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17664471
19.
Genome-wide map of nucleosome acetylation and methylation in yeast.
Cell
; 122(4): 517-27, 2005 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-16122420
20.
Program-specific distribution of a transcription factor dependent on partner transcription factor and MAPK signaling.
Cell
; 113(3): 395-404, 2003 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12732146